Multiple clonal MLL fusions in a patient receiving CHOP-based chemotherapy

Shyh Jen Shih, Joseph Fass, Vincent Buffalo, Dawei Lin, Sheetal P. Singh, Manuel O. Diaz, Andrew T M Vaughan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

MLL rearrangements were analysed in the blood of a patient receiving chemotherapy for diffuse large B-cell lymphoma using inverse polymerase chain reaction targeting exon 12, parallel sequencing and a custom algorithm design. Of thirteen MLL rearrangements detected, five were capable of generating MLL fusion genes, including MLL-MLLT3, the most common fusion in acute myeloid leukaemia (AML). Other fusions, all previously clinically unobserved, included MLL-NKD1, a fusion to the negative regulator of Wnt/β-catenin signaling, a pathway linked to leukaemic cell proliferation. The majority of the fusions exhibited clonal persistence from before treatment until 6 months post-chemotherapy, suggesting the fusions may confer a survival advantage to the mutant clone. MLL breakpoints were partly clustered at a specific location, indicating commonality in the process of their formation. Further, the same MLL breakpoint location exhibited a 50-100-fold increase in C to T transitions, consistent with attack by activation-induced cytidine deaminase (AICDA). As is also observed in AML and acute lymphoblastic leukaemia, in this single patient setting, MLL is capable of interacting with multiple fusion partners. This finding defines a discrete site of MLL susceptibility to fragmentation, linked to possible deregulation of AICDA function.

Original languageEnglish (US)
Pages (from-to)50-57
Number of pages8
JournalBritish Journal of Haematology
Volume159
Issue number1
DOIs
StatePublished - Oct 2012

Fingerprint

Acute Myeloid Leukemia
Drug Therapy
Catenins
Lymphoma, Large B-Cell, Diffuse
Sexual Partners
Gene Fusion
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Exons
Clone Cells
Cell Proliferation
Polymerase Chain Reaction
Survival
AICDA (activation-induced cytidine deaminase)
Therapeutics

Keywords

  • Activation induced cytidine deaminase
  • C to T transition
  • Clonal MLL fusion
  • MLL rearrangement
  • Therapy-related acute myeloid leukamia

ASJC Scopus subject areas

  • Hematology

Cite this

Multiple clonal MLL fusions in a patient receiving CHOP-based chemotherapy. / Shih, Shyh Jen; Fass, Joseph; Buffalo, Vincent; Lin, Dawei; Singh, Sheetal P.; Diaz, Manuel O.; Vaughan, Andrew T M.

In: British Journal of Haematology, Vol. 159, No. 1, 10.2012, p. 50-57.

Research output: Contribution to journalArticle

Shih, Shyh Jen ; Fass, Joseph ; Buffalo, Vincent ; Lin, Dawei ; Singh, Sheetal P. ; Diaz, Manuel O. ; Vaughan, Andrew T M. / Multiple clonal MLL fusions in a patient receiving CHOP-based chemotherapy. In: British Journal of Haematology. 2012 ; Vol. 159, No. 1. pp. 50-57.
@article{10425cbea37d4981af1e71ad7a745d7f,
title = "Multiple clonal MLL fusions in a patient receiving CHOP-based chemotherapy",
abstract = "MLL rearrangements were analysed in the blood of a patient receiving chemotherapy for diffuse large B-cell lymphoma using inverse polymerase chain reaction targeting exon 12, parallel sequencing and a custom algorithm design. Of thirteen MLL rearrangements detected, five were capable of generating MLL fusion genes, including MLL-MLLT3, the most common fusion in acute myeloid leukaemia (AML). Other fusions, all previously clinically unobserved, included MLL-NKD1, a fusion to the negative regulator of Wnt/β-catenin signaling, a pathway linked to leukaemic cell proliferation. The majority of the fusions exhibited clonal persistence from before treatment until 6 months post-chemotherapy, suggesting the fusions may confer a survival advantage to the mutant clone. MLL breakpoints were partly clustered at a specific location, indicating commonality in the process of their formation. Further, the same MLL breakpoint location exhibited a 50-100-fold increase in C to T transitions, consistent with attack by activation-induced cytidine deaminase (AICDA). As is also observed in AML and acute lymphoblastic leukaemia, in this single patient setting, MLL is capable of interacting with multiple fusion partners. This finding defines a discrete site of MLL susceptibility to fragmentation, linked to possible deregulation of AICDA function.",
keywords = "Activation induced cytidine deaminase, C to T transition, Clonal MLL fusion, MLL rearrangement, Therapy-related acute myeloid leukamia",
author = "Shih, {Shyh Jen} and Joseph Fass and Vincent Buffalo and Dawei Lin and Singh, {Sheetal P.} and Diaz, {Manuel O.} and Vaughan, {Andrew T M}",
year = "2012",
month = "10",
doi = "10.1111/j.1365-2141.2012.09248.x",
language = "English (US)",
volume = "159",
pages = "50--57",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Multiple clonal MLL fusions in a patient receiving CHOP-based chemotherapy

AU - Shih, Shyh Jen

AU - Fass, Joseph

AU - Buffalo, Vincent

AU - Lin, Dawei

AU - Singh, Sheetal P.

AU - Diaz, Manuel O.

AU - Vaughan, Andrew T M

PY - 2012/10

Y1 - 2012/10

N2 - MLL rearrangements were analysed in the blood of a patient receiving chemotherapy for diffuse large B-cell lymphoma using inverse polymerase chain reaction targeting exon 12, parallel sequencing and a custom algorithm design. Of thirteen MLL rearrangements detected, five were capable of generating MLL fusion genes, including MLL-MLLT3, the most common fusion in acute myeloid leukaemia (AML). Other fusions, all previously clinically unobserved, included MLL-NKD1, a fusion to the negative regulator of Wnt/β-catenin signaling, a pathway linked to leukaemic cell proliferation. The majority of the fusions exhibited clonal persistence from before treatment until 6 months post-chemotherapy, suggesting the fusions may confer a survival advantage to the mutant clone. MLL breakpoints were partly clustered at a specific location, indicating commonality in the process of their formation. Further, the same MLL breakpoint location exhibited a 50-100-fold increase in C to T transitions, consistent with attack by activation-induced cytidine deaminase (AICDA). As is also observed in AML and acute lymphoblastic leukaemia, in this single patient setting, MLL is capable of interacting with multiple fusion partners. This finding defines a discrete site of MLL susceptibility to fragmentation, linked to possible deregulation of AICDA function.

AB - MLL rearrangements were analysed in the blood of a patient receiving chemotherapy for diffuse large B-cell lymphoma using inverse polymerase chain reaction targeting exon 12, parallel sequencing and a custom algorithm design. Of thirteen MLL rearrangements detected, five were capable of generating MLL fusion genes, including MLL-MLLT3, the most common fusion in acute myeloid leukaemia (AML). Other fusions, all previously clinically unobserved, included MLL-NKD1, a fusion to the negative regulator of Wnt/β-catenin signaling, a pathway linked to leukaemic cell proliferation. The majority of the fusions exhibited clonal persistence from before treatment until 6 months post-chemotherapy, suggesting the fusions may confer a survival advantage to the mutant clone. MLL breakpoints were partly clustered at a specific location, indicating commonality in the process of their formation. Further, the same MLL breakpoint location exhibited a 50-100-fold increase in C to T transitions, consistent with attack by activation-induced cytidine deaminase (AICDA). As is also observed in AML and acute lymphoblastic leukaemia, in this single patient setting, MLL is capable of interacting with multiple fusion partners. This finding defines a discrete site of MLL susceptibility to fragmentation, linked to possible deregulation of AICDA function.

KW - Activation induced cytidine deaminase

KW - C to T transition

KW - Clonal MLL fusion

KW - MLL rearrangement

KW - Therapy-related acute myeloid leukamia

UR - http://www.scopus.com/inward/record.url?scp=84866318176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866318176&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2012.09248.x

DO - 10.1111/j.1365-2141.2012.09248.x

M3 - Article

VL - 159

SP - 50

EP - 57

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -